quilizumab
mAbexperimental
Quilizumab (INN) is a humanized monoclonal antibody designed for the treatment of asthma. It binds to IGHE. — Wikipedia
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2010 (NCT01160861)
Timeline
Indications
Mechanism of action
- Ig epsilon chain C regionINHIBITOR
IGHE inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaQuilizumab ↗
- ChEMBLCHEMBL2109456 ↗
Also known as
- anti-m1'
- anti-m1 prime
- memp1972a
- mep1972a
- quilizumab
- quilizumab
- rg-7449
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01987947 | Phase 2 | Dec 1, 2013 | Genentech |
| NCT01582503 | Phase 2 | Apr 1, 2012 | Genentech |
| NCT01196039 | Phase 2 | Dec 1, 2010 | Genentech |
| NCT01160861 | Phase 1 | Jul 1, 2010 | Genentech |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 4 | 4 | 2 | 2010 |
1 organizations
Page 1 / 1